Tago, Megumi

写真a

Affiliation

Faculty of Pharmacy, Department of Pharmacy 衛生化学講座 ( Shiba-Kyoritsu )

Position

Professor

Career 【 Display / hide 】

  • 2006.06
    -
    Present

    2003年4月～2006年5月 米国留学 2006年6月 共立薬科大学薬学部生化学講座　助手 (2007年４月より助教） 2008年4月 慶應義塾大学薬学部生化学講座　助教 2009年4月 慶應義塾大学薬学部生化学講座　専任講師 2014年4月 慶應義塾大学薬学部衛生化学講座 准教授

Page Top ▲

Academic Background 【 Display / hide 】

  • 1998.03

    共立薬科大学, 薬学部, 薬学科

    University, Graduated

  • 2003.03

    共立薬科大学大学院, 薬学研究科, 分子生物学、生化学

    Graduate School, Completed, Doctoral course

Page Top ▲

Academic Degrees 【 Display / hide 】

  • 博士（薬学）, 共立薬科大学, Coursework, 2003.03

Page Top ▲
 

Research Areas 【 Display / hide 】

  • Life Science / Pharmaceutical hygiene and biochemistry (Biological System Pharmaceutical Science)

Page Top ▲

Research Keywords 【 Display / hide 】

  • JAK2、STAT、erythropoietin、NF-kappaB

Page Top ▲

Research Themes 【 Display / hide 】

  • Analysis of cytokine signaling pathway, 

    2006
    -
    Present

Page Top ▲
 

Books 【 Display / hide 】

  • IL-33レセプターのシグナル伝達.

    笠原 忠、多胡めぐみ., 科学評論社, 2011.03

Page Top ▲

Papers 【 Display / hide 】

  • DDX5 is required for JAK2V617F-induced cell proliferation and tumorigenesis independent of its RNA helicase activity

    Takeda K., Tago K., Ohta S., Nakazawa Y., Funakoshi-Tago M.

    Cellular Signalling 138 2026.02

    Research paper (scientific journal), Last author, Corresponding author, Accepted,  ISSN  08986568

    　View Summary

    The constitutively active Janus kinase 2 mutant (JAK2V617F) is a major driver of myeloproliferative neoplasms (MPNs). Our previous studies demonstrated that JAK2V617F upregulates the expression of the RNA helicase DDX5 via activation of the transcription factor, signal transducer and activator of transcription 5 (STAT5). Furthermore, DDX5 facilitates mechanistic target of rapamycin (mTOR) signaling, thereby promoting the proliferation and tumorigenic potential of MPN cells. However, whether the RNA helicase activity of DDX5 is essential for JAK2V617F-driven oncogenesis remained unclear. In this study, we investigated the role of DDX5 in JAK2V617F-induced transformation by knocking down DDX5 in Ba/F3 cells expressing JAK2V617F and the erythropoietin receptor (V617F/EpoR cells), followed by reconstitution with either wild-type DDX5 or the helicase-deficient mutant K144N. DDX5 knockdown suppressed activation of the mTOR pathway, resulting in reduced proliferation and increased apoptosis in V617F/EpoR cells. In contrast, reconstitution with either wild-type DDX5 or the K144N mutant restored mTOR pathway activation, enhanced proliferation, and suppressed apoptosis. Furthermore, transplantation experiments using nude mice showed that DDX5 knockdown inhibited JAK2V617F-mediated tumor formation and hepatosplenomegaly, whereas reconstitution with DDX5 or the K144N mutant reversed these effects. These findings demonstrate that the RNA helicase activity of DDX5 is dispensable for JAK2V617F-induced transformation. These findings suggest that DDX5 promotes oncogenesis through helicase-independent mechanisms and represents a potential therapeutic target in JAK2V617F-driven malignancies.

  • KMN003 activates Nrf2 via disruption of the Keap1-Nrf2 interaction and p38-dependent transcriptional regulation

    Komeda K., Toyoshima K., Yasuda D., Ishida H., Kojima K., Osawa M., Hirano T., Ohe T., Tago K., Funakoshi-Tago M.

    Cellular Signalling 137 2026.01

    Research paper (scientific journal), Last author, Corresponding author, Accepted,  ISSN  08986568

    　View Summary

    Nuclear factor erythroid 2-related factor 2 (Nrf2) is a transcription factor that plays a crucial role in cellular defenses against oxidative stress and inflammation. Under normal conditions, Kelch-like ECH-associated protein 1 (Keap1), a ubiquitin ligase adaptor, binds to Nrf2, facilitating its ubiquitination and subsequent degradation via the proteasome. In this study, we investigated the properties of KMN003, a novel Nrf2 activator specifically designed to stabilize Nrf2 by disrupting its interaction with Keap1. X-ray crystallographic analysis revealed that KMN003 binds to the DGR-Cul3 (DC) domain of Keap1, occupying the Nrf2 interaction site. An AlphaScreen assay further showed that KMN003 effectively inhibits the binding between the Keap1 DC domain and the DLG motif of Nrf2 (IC₅₀ = 300 nM). We also investigated the mechanism of Nrf2 activation by KMN003 and its anti-inflammatory properties using murine macrophage-like RAW264.7 cells. KMN003 significantly reduced the lipopolysaccharide (LPS)-induced production of nitric oxide, CCL2, and tumor necrosis factor-alpha (TNFα) as well as the mRNA expression of inducible nitric oxide synthase, CCL2, and TNFα, which are essential inflammatory markers. KMN003 strongly inhibited nuclear translocation and transcriptional activation of nuclear factor-kappa B (NF-κB), a central regulator of inflammatory gene expression. KMN003 did not affect the LPS-induced phosphorylation of ERK or JNK, but strongly induced p38 phosphorylation in the absence of the LPS stimulation. The inhibition of p38 with SB203580 blocked KMN003-induced Nrf2 transcriptional activation despite promoting Nrf2 accumulation. These results highlight KMN003 as a promising anti-inflammatory drug that selectively stabilizes and activates Nrf2 via the p38 pathway.

  • The critical role of the phosphorylation of STAT3 at Y705 in ALCL-associated NPM-ALK-induced transforming activity.

    Lin, X., Korai, A., Nakazawa, Y., Tago, K., Funakoshi-Tago, M

    Cellular signalling 136   112128 2025.12

    Research paper (scientific journal), Joint Work, Last author, Corresponding author, Accepted

  • TRPV1 attenuates epithelial-mesenchymal transition via calpain-protein tyrosine phosphatase pathway in lens epithelial cells

    Nakazawa Y., Nishizawa F., Kawata S., Sugiyama Y., Nagai N., Yamamoto N., Funakoshi-Tago M.

    Experimental Eye Research 258 2025.09

    Research paper (scientific journal), Last author,  ISSN  00144835

    　View Summary

    TRPV1, which is widely expressed throughout the body, is a non-selective cation channel activated by capsaicin. We previously reported that TRPV1 activation suppressed TGFβ2-induced epithelial-mesenchymal transition (EMT) by inhibiting Epidermal Growth Factor Receptor (EGFR) phosphorylation in lens epithelial cells (Sugiyama et al., 2021). However, the detailed molecular mechanism remains unclear. In this study, we focused on the calpain–protein tyrosine phosphatase (PTP) pathway to elucidate the detailed mechanism underlying TRPV1-induced EMT suppression. Calpain and PTP inhibitors mitigated the suppressive effect of capsaicin on TGFβ2-induced EMT in vitro and ex vivo. Finally, we shown that CalpainS1 and PTPN9 overexpression abrogated the effect of capsaicin on EMT in lens epithelial cells. Our findings indicate that calpain and PTP proteins are good candidates for preventing EMT after cataract surgery.

  • Metabolic reprogramming by PRDM16 drives cytarabine resistance in acute myeloid leukemia

    Ikeda J., Kunimoto H., Saito Y., Tsujimoto S.I., Takeuchi M., Miura A., Kurosawa T., Murakami K., Kato I., Funakoshi-Tago M., Yokoyama A., Shiba N., Adachi S., Tomizawa D., Tamura T., Ito S., Nakajima H.

    Haematologica 110 ( 11 ) 2647 - 2660 2025.06

    Accepted,  ISSN  03906078

    　View Summary

    Acute myeloid leukemia (AML) patients with high PRDM16 expression frequently experience induction failure and have a poor prognosis. However, the molecular mechanisms underlying these clinical features remain elusive. We found that murine AML cells transformed by MLL::AF9 fusion and oncogenic short-isoform Prdm16 overexpression (hereafter, MF9/sPrdm16) exhibited resistance to cytarabine (AraC), but not to anthracycline, both in vitro and in vivo. Intriguingly, MF9/sPrdm16 cells displayed a gene expression signature of high oxidative phosphorylation (OxPHOS) and increased mitochondrial respiration. The inhibition of mitochondrial respiration with metformin or tigecycline abrogated AraC resistance in MF9/sPrdm16 cells via an energetic shift toward low OxPHOS status. Furthermore, sPrdm16 up-regulated Myc and the glutamine transporter Slc1a5, activating the TCA cycle and glutaminolysis. Of note, both OxPHOS and MYC-target gene signatures were significantly enriched in AML patient samples with high PRDM16 expression. Together, we showed that PRDM16 overexpression activates mitochondrial respiration through metabolic reprogramming via the MYC-SLC1A5-Glutaminolysis axis, thereby conferring AraC resistance on AML cells. These results suggest that targeting mitochondrial respiration might be a novel treatment strategy to overcome chemoresistance in AML patients with high PRDM16 expression.

display all >>

Page Top ▲

Papers, etc., Registered in KOARA 【 Display / hide 】

display all >>

Page Top ▲

Reviews, Commentaries, etc. 【 Display / hide 】

  • 炎症メディエーターと細胞 IL-1.

    笠原 忠、多胡めぐみ.

    炎症・再生医学事典(松島綱治、西脇徹編) (朝倉書店)  0   52-54 2009.04

    Article, review, commentary, editorial, etc. (scientific journal), Joint Work

Page Top ▲

Presentations 【 Display / hide 】

  • Anti-cataract effect of coffee intake on selenite-induced cataract in rat

    TAGO Megumi

    日本薬学会第136年会（横浜）, 

    2016.03
    , 

    Poster presentation

  • Inhibitory effect of ParvifloronE on TNFa signaling pathway

    TAGO Megumi

    日本薬学会第136年会（横浜）, 

    2016.03
    , 

    Poster presentation

  • Anti-inflammatory activity of Coffee extract

    TAGO Megumi

    日本薬学会第136年会（横浜）, 

    2016.03
    , 

    Poster presentation

  • The role of DDX5 in JAK2 V617F mutant – induced transformation.

    TAGO Megumi

    日本薬学会第136年会（横浜）, 

    2016.03
    , 

    Poster presentation

  • Mechanism of NPM-ALK positive cells apoptosis induced by crizotinib

    TAGO Megumi

    日本薬学会第136年会（横浜）, 

    2016.03
    , 

    Poster presentation

display all >>

Page Top ▲

Research Projects of Competitive Funds, etc. 【 Display / hide 】

  • Elucidation of pathogenesis of anaplastic large cell lymphoma via STAT3 target genes

    2023.04
    -
    2026.03

    基盤研究(C), Principal investigator

  • エリスロポエチン受容体結合分子を介した慢性骨髄増殖性腫瘍の発症機序の解明

    2020.04
    -
    2023.03

    MEXT,JSPS, Grant-in-Aid for Scientific Research, Grant-in-Aid for Scientific Research (C), Principal investigator

  • エリスロポエチン受容体のリン酸化を介した慢性骨髄増殖性腫瘍の発症機序の解明

    2017.04
    -
    2020.03

    MEXT,JSPS, Grant-in-Aid for Scientific Research, Grant-in-Aid for Scientific Research (C), Principal investigator

Page Top ▲

Awards 【 Display / hide 】

  • 柿内三郎記念奨励研究賞第11回（2014年）

    多胡　めぐみ, 2014.10, 日本生化学会, 「定量的リン酸化プロテオミクスによる慢性骨髄増殖性腫瘍の発症機構の解析」

    Type of Award： Award from Japanese society, conference, symposium, etc.

  • 第11回(2014年）柿内三郎記念奨励研究賞

    多胡　めぐみ, 2014.10, 日本生化学会, 定量的リン酸化プロテオミクスによる慢性骨髄増殖性腫瘍の発症機構の解析

  • 平成22年度関東支部奨励賞

    Tago M., 2012.10, 日本薬学会, JAK2 変異体のシグナル伝達解析による真性赤血球増加症発症機構の解明.

  • FEBS Letters Young Group Leader Award 2011

    Tago M., 2012.09, FEBS Letters, FEBS Letters Young Group Leader Award 2012.

  • 2012 FEBS Letters Young Group Leader Award

    TAGO MEGUMI, 2012.09, FEBS, Aurora kinase A critically contributes to the resistance to anti-cancer drug cisplatin in JAK2 V617F mutant-induced transformed cells

    Type of Award： International academic award (Japan or overseas)

display all >>

Page Top ▲
 

Courses Taught 【 Display / hide 】

  • TOXICOLOGICAL SCIENCES

    2025

  • STUDY OF MAJOR FIELD: (HYGIENIC CHEMISTRY)

    2025

  • SEMINAR: (HYGIENIC CHEMISTRY)

    2025

  • RESEARCH FOR BACHELOR'S THESIS 1

    2025

  • PUBLIC HEALTH

    2025

display all >>

Page Top ▲
 

Memberships in Academic Societies 【 Display / hide 】

  • 日本薬学会、日本生化学会、日本分子生物学会

    　
Page Top ▲

Committee Experiences 【 Display / hide 】

  • 2012.04
    -
    2014.03

    トピックス小委員, 日本薬学会

Page Top ▲